Neurocrine Biosciences (NBIX) Interest & Investment Income (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Interest & Investment Income for 17 consecutive years, with $12.4 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Interest & Investment Income fell 39.81% year-over-year to $12.4 million; the trailing twelve-month figure through Jun 2026 stood at $88.5 million (changed 0.34% YoY), and the FY2025 full-year result was $90.3 million, down 0.77% from the prior year.
• Interest & Investment Income retreated to $12.4 million in Q2 2026 per NBIX's latest filing, from $28.1 million in the prior quarter.
• Across five years, Interest & Investment Income topped out at $28.1 million in Q1 2026 and bottomed at $200000.0 in Q3 2022.
• Historically, Interest & Investment Income has averaged $15.5 million across 5 years, with a median of $19.8 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Interest & Investment Income slumped 75.0% in 2022, then soared 7150.0% in 2023.
• Over 5 years, Interest & Investment Income stood at $1.3 million in 2022, then soared by 1353.85% to $18.9 million in 2023, then grew by 19.05% to $22.5 million in 2024, then grew by 14.67% to $25.8 million in 2025, then plunged by 51.94% to $12.4 million in 2026.
• According to Business Quant data, Interest & Investment Income over the past three periods registered $12.4 million, $28.1 million, and $25.8 million for Q2 2026, Q1 2026, and Q4 2025 respectively.